EMEA-003201-PIP01-22
Submitted by Anonymous (not verified) on 10 July 2024 - 8:45
EMEA-003201-PIP01-22
EMEA-002619-PIP02-23
Submitted by Anonymous (not verified) on 10 July 2024 - 8:40
EMEA-002619-PIP02-23
EMEA-002597-PIP08-22
Submitted by Anonymous (not verified) on 10 July 2024 - 8:34
EMEA-002597-PIP08-22
Human medicines European public assessment report (EPAR): Qalsody, Tofersen, Date of authorisation: 29/05/2024, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 16:35
Human medicines European public assessment report (EPAR): Qalsody, Tofersen, Date of authorisation: 29/05/2024, Revision: 1, Status: Authorised
New Fee Regulation working arrangements
Submitted by Anonymous (not verified) on 9 July 2024 - 16:06
New Fee Regulation working arrangements
Human medicines European public assessment report (EPAR): Duloxetine Lilly, duloxetine, Date of authorisation: 08/12/2014, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 14:43
Human medicines European public assessment report (EPAR): Duloxetine Lilly, duloxetine, Date of authorisation: 08/12/2014, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Cymbalta, duloxetine, Date of authorisation: 17/12/2004, Revision: 33, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 14:43
Human medicines European public assessment report (EPAR): Cymbalta, duloxetine, Date of authorisation: 17/12/2004, Revision: 33, Status: Authorised
Human medicines European public assessment report (EPAR): Yentreve, duloxetine, Date of authorisation: 11/08/2004, Revision: 29, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 14:37
Human medicines European public assessment report (EPAR): Yentreve, duloxetine, Date of authorisation: 11/08/2004, Revision: 29, Status: Authorised
Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Date of authorisation: 01/10/2008, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 14:20
Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Date of authorisation: 01/10/2008, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Xospata, gilteritinib, Date of authorisation: 24/10/2019, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 14:13
Human medicines European public assessment report (EPAR): Xospata, gilteritinib, Date of authorisation: 24/10/2019, Revision: 7, Status: Authorised